The legacy of Viagra, and its developer copyright, presents a complex case study for investors. Initially a blockbuster drug, generating billions in revenue , its intellectual property lapse created a wave of knock-off medications, significantly eroding its dominance. While specific firms may try to capitalize on similar conditions , the present la